Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Lancet Oncology

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(09)70354-7PMID 20036194PMCID PMC2941877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

  2010cited by this paper
• The insulin‐like growth factor system and sarcomas

  2009cited by this paper
• Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor

  2009cited by this paper
• Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

  2009cited by this paper
• Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.

  2008cited by this paper
• A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

  2008cited by this paper
• A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma

  2007cited by this paper
• Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance.

  2007cited by this paper
• A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors

  2007cited by this paper
• The role of the IGF system in cancer growth and metastasis: overview and recent insights.

  2007cited by this paper
• Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

  2007cited by this paper
• Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

  2007cited by this paper
• Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines

  2007cited by this paper
• Involvement of insulin-like growth factor-I in the control of glucose homeostasis.

  2006cited by this paper
• Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

  2006cited by this paper
• Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.

  2006cited by this paper
• The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge

  2005cited by this paper
• Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

  2005cited by this paper
• Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871

  2005cited by this paper
• Mechanisms of sarcoma development

  2003cited by this paper
• Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.

  2003cited by this paper
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

  2002cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper
• Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect.

  1998cited by this paper
• Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes

  1996cited by this paper
• Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.

  1992cited by this paper
• Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

  1987cited by this paper
• The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor.

  1982cited by this paper

• Mapping Knowledge Structure and Themes Trends of Ewing Sarcoma: A Text-Mining Study

  2025cites this paper
• Tyrosine kinase inhibitors in Ewing’s sarcoma: a systematic review

  2025cites this paper
• Delayed growth of SK-ES-1 Ewing sarcoma tumors associated with reduced expression and activity of Trk receptors, PI3K, and IGF1R

  2025cites this paper
• Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature

  2025cites this paper
• mTORC2 inhibition reduces tumor burden via STAT1 activation and enhanced response to anti–PD-L1 therapy

  2025cites this paper
• Overall review of curative impact and barriers of CAR-T cells in osteosarcoma

  2024cites this paper
• EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities

  2024cites this paper
• Anti-PEc: Development of a novel monoclonal antibody against prostate cancer

  2024cites this paper
• Signaling pathways and targeted therapies in Ewing sarcoma.

  2024cites this paper
• Redundant Signaling as the Predominant mechanism for Resistance to Antibodies Targeting IGF-1R in Cells Derived from Childhood Sarcoma.

  2023cites this paper
• CB65 and novel CB65 liposomal system suppress MG63 and Saos-2 osteosarcoma cell growth in vitro

  2023cites this paper
• Antitumor Effects of β-Elemene Through Inducing Autophagy-Mediated Apoptosis in Ewing Sarcoma Family Tumor Cells

  2023cites this paper
• Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

  2023cites this paper
• EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis

  2023cites this paper
• Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma.

  2023cites this paper
• Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

  2023cites this paper
• PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas

  2023cites this paper
• Renal primitive neuroectodermal tumor: A rare case with a good prognosis

  2023cites this paper
• Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma

  2023cites this paper
• Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

  2023cites this paper
• Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

  2023cites this paper
• EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression

  2022cites this paper
• Personalised pharmacotherapy options for soft tissue sarcomas

  2022cites this paper
• Challenges of Systemic Therapy Investigations for Bone Sarcomas

  2022cites this paper
• Identification of new therapeutic targets of bone cancers by proteomic strategies

  2022cites this paper
• Cancer stem cells and chemoresistance in Ewing sarcoma.

  2022cites this paper
• Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

  2022cites this paper
• Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives

  2022cites this paper
• An institutional review of treatment outcomes in extraosseous Ewing's sarcoma- the largest Asian experience.

  2022cites this paper
• Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer

  2022cites this paper
• New therapeutic advances of bone sarcomas

  2022cites this paper
• Sarcomas of Bone and Soft Tissues in Children and Adolescents

  2021cites this paper
• Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

  2021cites this paper
• Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

  2021cites this paper
• The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

  2021cites this paper
• Recent advances in drug formulation development for targeting lung cancer

  2021cites this paper
• A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors

  2021cites this paper
• Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review

  2021cites this paper
• Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options

  2021cites this paper
• Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research

  2021cites this paper
• Targeted therapy in metastatic, recurrent and refractory Ewing sarcoma and osteogenic sarcoma. Review of literature

  2021cites this paper
• Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

  2020cites this paper
• Contemporary Approach to Therapy for Ewing Sarcoma

  2020cites this paper
• Current Status and Perspectives of Patient-Derived Models for Ewing’s Sarcoma

  2020cites this paper
• Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

  2020cites this paper
• Systematic literature review of clinical outcomes in adults with metastatic or advanced synovial sarcoma.

  2020cites this paper
• A pharmacokinetics primer for preclinical nanomedicine research

  2020cites this paper
• Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

  2020cites this paper
• Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

  2020cites this paper
• Advances in insulin-like growth factor biology and -directed cancer therapeutics.

  2020cites this paper
• Precision Medicine in Soft Tissue Sarcoma Treatment

  2020cites this paper
• The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives

  2020cites this paper
• A Prognostic Model for the Overall Survival of Patients with Ewing's Sarcoma

  2020cites this paper
• Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma

  2020cites this paper
• Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions: Clinical, Radiological and Histological Correlations - The Rizzoli Case Archive

  2020cites this paper
• Biology of Ewing Sarcoma

  2019cites this paper
• Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A

  2019cites this paper
• Therapeutic Targeting of the IGF Axis

  2019cites this paper
• Precision medicine approaches for the management of Ewing sarcoma: current perspectives

  2019cites this paper
• Insulin-like growth factor (IGF) signaling in T-cell acute lymphoblastic leukemia.

  2019cites this paper
• Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection.

  2019cites this paper
• Effects of mindfulness-based stress reduction combined with music therapy on pain, anxiety, and sleep quality in patients with osteosarcoma

  2019cites this paper
• Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

  2019cites this paper
• Industry corner: perspectives and controversies Joint

  2018cites this paper
• Antibody based therapy for childhood solid cancers

  2018cites this paper
• Growth and Growth Factors

  2018cites this paper
• Translocation-Related Sarcomas

  2018cites this paper
• Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.

  2018cites this paper
• Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro

  2018cites this paper
• Current Status of Proteomics in Ewing's Sarcoma

  2018cites this paper
• Establishment of a novel patient-derived Ewing’s sarcoma cell line, NCC-ES1-C1

  2018cites this paper
• Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R

  2018cites this paper
• Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

  2018cites this paper
• Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas

  2018cites this paper
• Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

  2018cites this paper
• Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor

  2018cites this paper
• Systemic Treatment for Adults with Synovial Sarcoma

  2018cites this paper
• Upregulation of IGF-1 R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients

  2017cites this paper
• Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

  2017cites this paper
• Anti-angiogenesis target therapy for advanced osteosarcoma

  2017cites this paper
• Bone Sarcomas in the Adolescent and Young Adult Population

  2017cites this paper
• Salvage Therapy and Palliative Care for Metastatic Sarcoma

  2017cites this paper
• Managing sarcoma: where have we come from and where are we going?

  2017cites this paper
• Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective

  2017cites this paper
• Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.

  2017cites this paper
• IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy.

  2017cites this paper
• IGF‐I regulates HT1080 fibrosarcoma cell migration through a syndecan‐2/Erk/ezrin signaling axis

  2017cites this paper
• EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1

  2017cites this paper
• Assessment of Chemotherapy Response in Ewing Sarcoma.

  2016cites this paper
• Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group

  2016cites this paper
• The value of research collaborations and consortia in rare cancers.

  2016cites this paper
• MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

  2016cites this paper
• Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.

  2016cites this paper
• Potential approaches to the treatment of Ewing's sarcoma

  2016cites this paper
• Innovative Exploratory Clinical Approaches for Relapsed and / or Refractory Metastatic Ewing ’ s Sarcoma

  2016cites this paper
• Assessment of Chemotherapy Response in Ewing Sarcoma: Response

  2016cites this paper
• Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.

  2016cites this paper
• Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC

  2016cites this paper
• No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone

  2016cites this paper
• Insulin-like Growth Factor Receptor Inhibition as Maintenance Therapy for Metastatic Ewing Sarcoma

  2016influential citation